Mohit Narang, MD

Mohit Narang, MD, is a medical hematologist and oncologist at Maryland Oncology Hematology.

Articles by Mohit Narang, MD

Community Oncology Must Adapt for CAR T, Bispecific Multiple Myeloma Care: Mohit Narang, MD

June 29th 2026

Mohit Narang, MD, discusses how community oncology practices can expand access to CAR T and bispecific therapies through better infrastructure and collaboration.

Brukinsa packaging | Image: BeOne Medicines

Safety Drives Decision to Move to Zanubrutinib in CLL

ByMohit Narang, MD,Hayden E. Klein

June 19th 2025

Switching From Ibrutinib to Zanubrutinib Improves Cardiac Safety and Workflow: Mohit Narang, MD

ByHayden E. Klein,Mohit Narang, MD

June 2nd 2025

Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac adverse effects and a reduced workload for Mohit Narang, MD, managing partner at Maryland Oncology Hematology.

Switching Patients With CLL From Ibrutinib for Zanubrutinib: Mohit Narang, MD

ByHayden E. Klein,Mohit Narang, MD

May 15th 2025

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton tyrosine kinase inhibitor.

Mohit Narang, MD

Articles by Mohit Narang, MD

Community Oncology Must Adapt for CAR T, Bispecific Multiple Myeloma Care: Mohit Narang, MD

Safety Drives Decision to Move to Zanubrutinib in CLL

Switching From Ibrutinib to Zanubrutinib Improves Cardiac Safety and Workflow: Mohit Narang, MD

Switching Patients With CLL From Ibrutinib for Zanubrutinib: Mohit Narang, MD

Latest Updated Articles

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Practices, Cut Patient Costs

Remote Monitoring Captured Between-Visit Symptom Swings in Myasthenia Gravis

Innovation Is Outpacing Reimbursement, Health System Execs Warn

SNAP Participation Linked to Smaller Colorectal Screening Gap